GUARINI: But could it boomerang back on the companies? Will I resent that if I had been taking Zocor for the last 10 years, and it
was $180 a month, that I am now paying $40?
WILKES: It depends if your relationship is with simvastatin or with Merck. If it's with Merck, the company has to tell the patient
what is coming, and why there is a price disparity. Right now, that information comes from the pharmacist.
BOKEN: The biggest opportunity is with life-saving drugs. If I get a cancer treatment that literally brings me back to life, then
I would be willing to continue to buy from the original manufacturer.
HUNTSMAN: If there is more pharmacovigilance, what will be required of generic companies? Will they have to take on the costs of expensive
risk-management programs? That may be a barrier to entry for some generic companies.
BREITSTEIN: And certainly an opportunity. Thank you all for participating.